Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma - Amsterdam 2025

Cutting-edge trial data on biologics for airway diseases: asthma, COPD, chronic rhinosinusitis with nasal polyps and chronic cough

Chair(s): Dave Singh, Florence Schleich

Session type: Oral presentation

Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma

Dave Singh

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma

Dave Singh

Replay

Poster

Abstract

Slides

Twice-yearly depemokimab demonstrates efficacy in patients with asthma and comorbid chronic rhinosinusitis with nasal polyps (CRSwNP): Phase III SWIFT-1/2 studies

Enrico Marco Heffler

Replay

Poster

Abstract

Slides

Depemokimab is associated with early and sustained improvements in patient-reported outcomes in CRSwNP: Data from the ANCHOR-1/2 trials

Marjolein Cornet

Replay

Poster

Abstract

Slides

Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study

Brian J. Lipworth

Replay

Poster

Abstract

Slides

Dupilumab efficacy in patients with asthma and allergic bronchopulmonary aspergillosis (ABPA)

Arnaud Bourdin

Replay

Poster

Abstract

Slides

Mepolizumab Following Hospitalisation for Severe Exacerbation of Eosinophilic COPD

Hamish Mcauley

Replay

Poster

Abstract

Slides

Mepolizumab for the treatment of refractory chronic cough with eosinophilic airways disease (MUCOSA): a randomized, double-blind, placebo-controlled trial

Nermin Diab

Replay

Poster

Abstract

Slides

Comparable pharmacokinetics (PK), safety and tolerability of astegolimab administered subcutaneously (SC) via abdomen, thigh or upper arm: a Phase I, single-dose study

Rebecca Saenz

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}